Ardelyx
Update in progressARDX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ardelyx, Inc. discovers, develops, and markets medicines to treat unmet medical needs in the United States and internationally. Its portfolio includes IBSRELA, a minimally absorbed oral therapy for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor to lower serum phosphorus in adults with chronic kidney disease on dialysis. Formerly Nteryx, Inc., the company changed its name to Ardelyx in June 2008 after being incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Company score
- Sentiment
- 0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.01
- Governance
- -0.25
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!